QCG
ATRA icon

Quadrant Capital Group’s Atara Biotherapeutics ATRA Stock Holding History

Quadrant Capital Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4
Closed -$351 – 2720
2022
Q4 		$351 Sell
4
-79
-95% -$8.23K ﹤0.01% 2655
2022
Q3 		$8K Buy
+83
New +$9.32K ﹤0.01% 1950

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Quadrant Capital Group's ATRA Position: Q1 2023 in Review

Quadrant Capital Group sold out of Atara Biotherapeutics (ATRA) in Q1 2023, closing a stake of 4 shares — an estimated $351 sold.

Quadrant Capital Group first reported a position in ATRA in Q3 2022 and held it in 2 quarters. The position peaked at $8K in Q3 2022. 125 funds tracked by Wall St. Rank hold ATRA as of Q1 2023.

  • Quadrant Capital Group reported no remaining Atara Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 4 Atara Biotherapeutics shares in Q1 2023, an estimated $351.
  • Quadrant Capital Group first reported a position in Atara Biotherapeutics in Q3 2022 and held it in 2 quarters.
  • Quadrant Capital Group's Atara Biotherapeutics position peaked at $8K in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2023.

Based on Quadrant Capital Group's 13F filing for Q1 2023, filed 11 May 2023.